Cetrorelix

證據等級: L5

預測適應症: 10 個

Cetrorelix: From Controlled Ovarian Stimulation to Hypertrichosis

One-Sentence Summary

Cetrorelix (internationally marketed as Cetrotide) is a gonadotropin-releasing hormone (GnRH) antagonist used in assisted reproductive technology to prevent premature LH surges during controlled ovarian stimulation. The TxGNN model predicts it may have potential for Hypertrichosis, with 0 clinical trials and 0 publications directly supporting this repurposing direction. The mechanistic rationale is indirect and limited to androgen-dependent subtypes of the condition, leaving this prediction at the level of model signal only.

Quick Overview

Item	Content
Original Indication	Prevention of premature LH surges during controlled ovarian stimulation (ART/IVF)
Predicted New Indication	Hypertrichosis
TxGNN Prediction Score	99.98%
Evidence Level	L5
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Cetrorelix is a synthetic decapeptide GnRH antagonist that competitively blocks GnRH receptors in the anterior pituitary, rapidly and reversibly suppressing the secretion of both LH and FSH. This leads to downstream suppression of gonadal sex hormone production—including testosterone in males and estrogen/progesterone in females. Its proven efficacy in controlled ovarian stimulation for IVF is recognized internationally (EU, USA under the brand name Cetrotide), though it is not currently marketed in Canada.

The proposed mechanistic pathway linking Cetrorelix to hypertrichosis runs as follows: GnRH antagonism → LH suppression → reduced testosterone production → attenuation of androgen-driven stimulation of hair follicles. Androgens are known to play a role in certain acquired forms of hypertrichosis—particularly those arising from hyperandrogenic states (e.g., polycystic ovary syndrome, adrenal tumours, exogenous androgen exposure)—where excess testosterone stimulates vellus-to-terminal hair conversion across androgen-sensitive body regions.

However, hypertrichosis is a clinically heterogeneous condition. Many subtypes—including congenital hypertrichosis lanuginosa, drug-induced hypertrichosis (e.g., from minoxidil, cyclosporine, phenytoin), and paraneoplastic hypertrichosis—are entirely independent of androgen signalling. For these subtypes, GnRH antagonism would have no mechanistic basis whatsoever. Even in androgen-dependent cases, more targeted approaches such as antiandrogens (spironolactone, cyproterone acetate) or 5α-reductase inhibitors are already available. The mechanistic link is therefore considered weak and highly indirect, and this TxGNN signal likely reflects the model’s recognition of the hormonal axis rather than a validated therapeutic connection.

Clinical Trial Evidence

Currently no related clinical trials registered for Cetrorelix in hypertrichosis.

Literature Evidence

Currently no related literature available for Cetrorelix in hypertrichosis.

Canada Market Information

Cetrorelix is currently not marketed in Canada. No Drug Identification Numbers (DINs) are on file with Health Canada.

Note: Cetrorelix is approved in other jurisdictions under the brand name Cetrotide (e.g., EMA approval in the EU; FDA approval in the USA) for the indication of controlled ovarian stimulation. A regulatory submission to Health Canada would be required before any commercial use in Canada.

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were available in this evidence pack.

General caution: As a peptide hormone antagonist administered by subcutaneous injection, Cetrorelix carries class-specific risks including hypersensitivity/anaphylaxis, injection-site reactions, and ovarian hyperstimulation syndrome (OHSS) in its approved ART context. These profiles would require re-evaluation for any new indication and patient population.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a TxGNN prediction score of 99.98%, this signal is unsupported by any clinical trial data or peer-reviewed literature specific to Cetrorelix and hypertrichosis (Evidence Level L5). The mechanistic pathway is indirect, applicable only to a narrow androgen-dependent subtype of hypertrichosis, and more targeted treatment alternatives already exist. In addition, Cetrorelix is not currently marketed in Canada, adding a significant regulatory barrier.

To proceed, the following is needed:

MOA confirmation: Retrieve complete DrugBank pharmacology profile and any published receptor-binding data to substantiate the GnRH → androgen suppression pathway in hair follicle biology
Safety baseline: Obtain full Canadian product monograph equivalent (or EMA/FDA prescribing information) to characterise warnings, contraindications, and drug interactions
Patient subpopulation definition: Identify a well-defined androgen-dependent hypertrichosis subgroup (e.g., hyperandrogenic women with confirmed elevated free testosterone) where GnRH suppression has mechanistic rationale
Preclinical signal: Establish whether any in vitro or animal model data support GnRH antagonist effects on hair follicle androgen responsiveness before investing in clinical exploration
Route feasibility: Evaluate whether subcutaneous injection (the existing delivery route) is acceptable and practical for a chronic dermatological indication, or whether alternative formulations would be required
Regulatory pathway: Confirm Health Canada requirements for a new indication in an unlicensed drug, including DIN application and clinical data package expectations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.